Building interpretable models for polypharmacy prediction in older chronic patients based on drug prescription records by Kocbek, S et al.
Submitted 11 April 2018
Accepted 17 September 2018










2018 Kocbek et al.
Distributed under
Creative Commons CC-BY 4.0
OPEN ACCESS
Building interpretable models for
polypharmacy prediction in older chronic
patients based on drug prescription
records
Simon Kocbek1,2,3, Primoz Kocbek4, Andraz Stozer5, Tina Zupanic6,
Tudor Groza1,7 and Gregor Stiglic4,8
1Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia
2Advanced Analytics Institute, Faculty of Engineering and IT, University of Technology, Sydney,
New South Wales, Australia
3Department of Computing and Information Systems, University of Melbourne, Melbourne, Victoria,
Australia
4 Faculty of Health Sciences, University of Maribor, Maribor, Slovenia
5 Institute of Physiology, Faculty of Medicine, University of Maribor, Maribor, Slovenia
6Healthcare Data Center, The National Institute of Public Health of the Republic of Slovenia, Ljubljana,
Slovenia
7 St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia
8 Faculty of Electrical Engineering and Computer Science, University of Maribor, Maribor, Slovenia
ABSTRACT
Background. Multimorbidity presents an increasingly common problem in older
population, and is tightly related to polypharmacy, i.e., concurrent use of multiple
medications by one individual. Detecting polypharmacy fromdrug prescription records
is not only related to multimorbidity, but can also point at incorrect use of medicines.
In this work, we build models for predicting polypharmacy from drug prescription
records for newly diagnosed chronic patients. We evaluate the models’ performance
with a strong focus on interpretability of the results.
Methods. A centrally collected nationwide dataset of prescription records was used to
perform electronic phenotyping of patients for the following two chronic conditions:
type 2 diabetesmellitus (T2D) and cardiovascular disease (CVD). In addition, a hospital
discharge dataset was linked to the prescription records. A regularized regressionmodel
was built for 11 different experimental scenarios on two datasets, and complexity of the
model was controlled with a maximum number of dimensions (MND) parameter.
Performance and interpretability of the model were evaluated with AUC, AUPRC,
calibration plots, and interpretation by a medical doctor.
Results. For the CVD model, AUC and AUPRC values of 0.900 (95% [0.898–0.901])
and 0.640 (0.635–0.645) were reached, respectively, while for the T2Dmodel the values
were 0.808 (0.803–0.812) and 0.732 (0.725–0.739). Reducing complexity of the model
by 65% and 48% for CVD and T2D, resulted in 3% and 4% lower AUC, and 4% and
5% lower AUPRC values, respectively. Calibration plots for our models showed that
we can achieve moderate calibration with reducing the models’ complexity without
significant loss of predictive performance.
Discussion. In this study, we found that it is possible to use drug prescription data
to build a model for polypharmacy prediction in older population. In addition, the
How to cite this article Kocbek et al. (2018), Building interpretable models for polypharmacy prediction in older chronic patients based
on drug prescription records. PeerJ 6:e5765; DOI 10.7717/peerj.5765
study showed that it is possible to find a balance between good performance and
interpretability of the model, and achieve acceptable calibration at the same time.
Subjects Drugs and Devices, Public Health, Statistics, Computational Science
Keywords Polypharmacy prediction, Cardiovascular disease, Diabetes type 2, Prescription data,
Clinical interpretability, Logistic regression
INTRODUCTION
Multimorbidity is becoming increasingly common, especially in older population. Despite
the improvements in chronic disease treatment, the prevalence of multimorbid patients
is still on the rise, although it is difficult to exactly define the multimorbidity (Willadsen
et al., 2016). However, it is known that prevalence of multimorbidity increases with
age (Calderón-Larrañaga et al., 2018). Polypharmacy or concurrent use of multiple
medications by one individual is becoming another major health concern and is tightly
related to multimorbidity. Especially in the older population, the number of concurrent
health conditions is directly related to a number of medications prescribed, eventually
resulting in polypharmacy (Hajjar, Cafiero & Hanlon, 2007).
Detecting polypharmacy from drug prescription records is not only related to
multimorbidity, but can also point at incorrect use of medicines. According to estimates
by the World Health Organisation (WHO) more than half of all medicines are prescribed,
dispensed or sold inappropriately, and that half of all patients fail to take them
correctly (WHO, 2012). In the scope of the third global patient safety challenge, WHO
addresses three areas of medication-related harm—i.e., high-risk situations, polypharmacy
and transitions of care (Sheikh et al., 2017). With the rapid introduction of the electronic
health records (EHR), particularly at the primary healthcare level, it will be possible
to effectively monitor and identify groups of patients or individuals at high risk for
drug-induced or related health problems (Molokhia & Majeed, 2017). Additionally, linking
different EHR repositories together (Kocbek et al., 2016) and solving challenges in capturing
the data in electronic form (Stiglic et al., 2017) will allow further improvements of data
driven techniques.
A great majority of studies on polypharmacy have focused on its potential negative
consequences, e.g., nonadherence, interactions, and adverse drug reactions. Some
researchers have also considered the effectiveness of interventions aimed at reducing
polypharmacy, however, the factors and conditions leading to polypharmacy have received
comparatively little attention. These factors can be broadly classified into four groups:
(i) factors related to the health care system (e.g., life expectancy and novel therapies),
(ii) factors related to patients (e.g., age and clinical conditions), (iii) factors related to
physicians (e.g., guidelines and prescribing habits), and (iv) the interaction between
patient and physician. In our study, we focused on medical therapy, more specifically
on medications taken in the last three months in older patients with newly diagnosed
chronic cardiovascular disease (CVD) type 2 diabetes mellitus (T2D) patients. Kanta et al.
(2016) demonstrate high prevalence of non-adherence problem as well as polypharmacy
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in patients with CVD and T2D where fears of drug toxicity are mentioned as a barrier to
taking medicines.
Machine learning is becoming indispensable for solving problems in many disciplines,
including healthcare. At the moment, we are witnessing the introduction of various
machine learning approaches in different fields of healthcare that can help the professionals
in improvement of diagnosis or prognosis and even displacing a lot of work done
by radiologists and anatomical pathologists (Obermeyer & Emanuel, 2016). However,
despite the ever-increasing prediction performance of the novel predictive modelling
techniques, most of them still lack interpretability to offer actionable support for healthcare
experts (Holzinger et al., 2017; Stiglic et al., 2012). Therefore, this study aims to offer more
insight into balancing the interpretability and predictive performance of the predictive
models in healthcare. More specifically, we evaluate different levels of interpretability
offered by regularized logistic regression modelling to predict polypharmacy based on
prescription data in CVD and T2D patients.
DATA AND METHODS
Study design and data source
Two separate nationwide data sources were available for this study. The first dataset
contained drug prescription records collected in Slovenia from 2008 to 2016, while the
second dataset contained Slovenian hospital discharge records (primary healthcare level)
from 2006 to 2016. Both datasets included patient identification information to allow
linkage of data between years 2008 and 2016. All the data was collected centrally by
National Institute of Public Health covering the whole population of Slovenia, which
presents an important advantage compared to decentralised datasets where data linkage is
not possible. The ‘‘Transparent reporting of amultivariable predictionmodel for individual
prognosis or diagnosis’’ (TRIPOD) (Collins et al., 2015) was followed.
Study setting
A total of 94,475,895 prescription entries for all patients who were prescribed at least one
medication for T2D or CVD were obtained covering 755,966 unique patients (i.e., 402,286
males and 349,892 females, while 3,788 patients contained different genders at different
time points and were later removed). The raw data contained 14 variables including
anonymised patient id, patient gender, patient’s geographical information, drug identifier,
and the patient’s doctor information. The hospital discharge data contained 1,740,610
entries covering 526,087 unique patients, who were prescribed at least one medication for
T2D or CVD in the time period between 2006 and 2016. The discharge data was provided
in two different formats, depending on time period when it was collected. Both formats
included general information about the patient (e.g., age or anonymised identifier) and
the admission (e.g., year and date of the hospitalisation or main diagnosis). International
Classification of Diseases, revision 10 (ICD-10) was used to define specific diagnosis.
ICD-encoding contains codes for diseases, signs and symptoms, abnormal findings,
complaints, social circumstances, and external causes of injury or diseases. The main
difference between the two hospital record formats was the number of ICD-10 codes. Data
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collected between 2006 and 2012 contained only primary and secondary diagnosis codes,
while data collected between 2013 and 2016 contained primary and up to 19 additional
diagnosis codes. To allow unbiased use of hospitalization data, only data from 2013 to 2016
was used in this study.
All records in both datasets were anonymised by the Slovenian National Institute of
Public Health using the following three steps. First, a random identifier was assigned to
each original patient identifier number to allow data linkage across both datasets. Second,
no age for the patients was provided, instead the patients were divided into age groups of
5 years. For example, the age group 0 would contain patients with ages from 0 to 4 years,
the age group 1 would contain patients with ages ranging from 5 to 9 years, etc. Finally,
only the year and the month of the prescription were given.
Anatomical Therapeutic Chemical Classification System (ATC) codes were used to
code the prescribed medications. ATC codes consist of up to 7 characters and provide the
following information:
•L1: indicates the anatomical main group (one letter).
•L2: the therapeutic main group (two digits).
•L3: the therapeutic/pharmacological subgroup (one character).
•L4: the chemical/therapeutic/pharmacological subgroup (one character).
•L5: the chemical substance (two digits).
Preprocessing of the data
First, we removed prescriptions for patients with different genders at different time points
(manual inspection revealed an error in data) and prescriptions with no ATC codes
(e.g., data entry errors or prescriptions of medical appliances). Next, for each ATC code,
we also included the ATC3 code, i.e., a shorter L3 version of the full ATC code (e.g., for
B01AA we would add B01).
Next, since the prevalence of polypharmacy increases by age, especially in older
population aged 65+ (Calderón-Larrañaga et al., 2018), only patients born before 1960
(to consider the age group window) were included in the study. Since the dataset did not
contain date of birth for patients, we used age groups to estimate dates of birth. For each
patient, we calculated the maximum possible year of birth (yb) from the patient’s age group
(ag ) and year (y) of when the prescription was issued:
yb(ag ,d)= y−ag ∗5.
Then we averaged all maximum possible years for each patient, rounded to the closest
integer, and got the final approximate year of birth. The mean of year of birth for the
755,966 unique patients in our data was 1946.
Finally, we merged hospitalisation discharge data with prescription records.
Electronic phenotyping
Electronic phenotyping is often described as the process of identifying patients with a
medical condition or characteristic (Banda et al., 2017). In our work we had to identify
patients with: (a) polypharmacy, and (b) newly diagnosed chronic CVD or T2D condition.
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Table 1 Selected ATC codes for CVD and T2D.
Condition ATC Description
T2D A10 Drugs used in diabetes.
B01AA, B01AC Cardiac agents (excl. ACE inhibators).
C01, C04A Antihypertensives.
C02, C07 Peripheral vasodilators.
CVD
C08, C09 E.g., Beta blocking agents, Calcium channel blockers.
We defined polypharmacy as a concurrent use of at least five medications. Concurrent
use was defined as all medications that were prescribed in three consecutive months
(e.g., January, February, March).
As patients with a chronic condition c we selected all those patients that were prescribed
at least one medication for c every three months, for a period of twelve months. Table 1
shows ATC codes for T2D and CVD. The latter were selected based on the recommendation
by Huber et al. (2013), which developed an updated and improved measure of patients’
chronic disease.
As mentioned in ’Study setting’, only data from 2013 until 2016 was used in the
phenotyping stage. Figure 1 illustrates the electronic phenotyping steps. We selected
January 2016 as the prediction time point (PTP) and filtered patients based on the chronic
disease and polypharmacy conditions. For the former, we selected all non-chronic CVD
and T2D that became chronic at PTP, and for the latter, we removed all patients with
polypharmacy before PTP.
Predictor and variables
Final datasets contained 678 and 1,225 predictor variables for T2D and CVD respectively.
The T2D dataset contained 44.9% of positive cases, while 21.8% of patients were positive
in the CVD dataset. The latter indicates an unbalanced dataset which represents additional
challenge for predictive techniques, and we had to consider this fact when evaluating
our models. The predictor variables were arbitrary selected form a 3-months window
before PTP and consisted of age, gender, hospitalisation, and ATC, ATC3 and ICD codes.
Hospitalisation, ATC and ICD codes were indicator values {0,1}, Age was numeric, while
Gender was a dichotomous variable. Table 2 presents statistics for predictive variables used
in the prediction model for both datasets. Note that Age represents mean age in years
(calculated from estimated year of birth), n for Male, Female and Hosp represents number
of instances, while m for #ATC, #ATC3 and #ICD represents number of variables with at
least one positive instance.
Predictive modeling
Advanced statistical methods were applied to find patterns in the datasets for both chronic
conditions, and a model to predict polypharmacy complications for patients was built.
As one of our goals was to build interpretable models to increase usability, we restricted









































Patients to keep 


























Patients to keep 
Patients to remove 
2016 
 	  	  	  	 	  	  	  	
2016 2015 PTP 
Chronic medication Polypharmacy 
Figure 1 Summary of filtering chronic and polypharmacy patients where two years of prescription
data are considered. First, all data is partitioned into time periods of three consecutive months. Each
three-month interval is used to: first, define the number of concurrent use of medications, and second,
check for T2D or CVD medications. Next, the year before prediction time point (PTP) is used to remove
all patients with previous polypharmacy (i.e., number of concurrent medications is higher than 4) or pre-
vious CVD or T2D chronic condition (i.e., at least one chronic medication is taken every 3 months). Fi-
nally, the year following PTP is used to select only the patients with a chronic condition, while polyphar-
macy in this year is used to define positive and negative patients.
Full-size DOI: 10.7717/peerj.5765/fig-1
model building to regularized linear models, where model complexity (dimensionality)
can be tuned. The latter also helps in avoiding overfitting, a problem in machine learning
where models do not generalise well. We experimented with both L1-norm (LASSO) and
broader elastic net regularization, however, the latter resulted in more complex modes with
no performance gain, therefore we report results only for LASSO. The generalized linear
model via penalized maximum likelihood LASSO regularization was used as defined by
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Table 2 Summary table for predictor variables.
Variable T2D CVD
Pos (n= 934) Neg (n= 1,147) Pos (n= 3,464) Neg (n= 12,495)
Age [95% CI years)] 66.51 [66.03–67.00] 65.34 [64.91–65.76] 67.69 [67.42–67.99] 65.72 [65.59–65.86]
Female [n (%)] 393 (42%) 437 (38%) 1,854 (54%) 5,761 (46%)
Male [n (%)] 541 (58%) 710 (62%) 1,610 (46%) 6,734 (54%)
Hosp [n (%)] 125 (13%) 137 (12%) 646 (19%) 1,484 (12%)
#ATC [m (%)] 246 (36%) 179 (26%) 352 (29%) 317 (26%)
#ATC3 [m (%)] 51 (8%) 43 (6%) 59 (5%) 56 (5%)
#ICD [m (%)] 234 (35%) 234 (35%) 510 (42%) 674 (55%)







where i represents observations and it’s negative log-likelihood contribution is noted as
l(y,n) with wi representing weights and tuning (shrinkage) parameter λ controlling the
overall strength of the penalty.
We further controlled the complexity of the model with the Maximal number of
dimensions (MND) parameter with values from 10 to 100 in steps of 10, where the
λ parameter was optimized with respect to the internal 5-fold cross validation. More
precisely, in the MND models the last λ value before the number of predictor variables
reaches MND is selected.
Model validation
To evaluate our models, we focused on their predictive performance, which we describe in
terms of discrimination and calibration. Discrimination measures the ability of a predictive
model to separate outcomes, while calibration refers to the extent of the bias in the outcome
of the model (Harrell, Lee & Mark, 1996). The discrimination can be measured by Area
Under ROC Curve (AUC), i.e., the probability that the classifier will rank a randomly
chosen positive case higher than a randomly chosen negative case. The ROC curve is
plotted with Sensitivity or True Positive Rate (TPR) against the Fall-out or False Positive
Rate (FPR), and AUC summarises the ROC curve into a single value by calculating the area
of the convex shape below ROC. To obtain more details on predictive performance we also
measured sensitivity, specificity, positive predictive value (PPV), negative predictive value
(NPV), average number of selected features and percentage of positively predicted cases.
It is said that a model is ‘‘calibrated’’ when the predicted probability of a class matches
the expected frequency of that class. Calibration can be visualized via a calibration plot,
which plots class probabilities against those predicted by a single or multiple classifiers.
In other words, calibration plots show observed proportion of events associated with a
model’s predicted risk, where the ideal calibration happens when both measures are equal.
However, Van Calster et al. (2016) defined a calibration hierarchy, with the lowest level 1
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(mean calibration or ‘‘calibration-in-the-large’’) and highest level 4 (strong calibration),
where they presented a strong case for usingmoderate or level 3 calibration (i.e., the average
predicted risk is equal to the actual average risk), which can be assessed via calibration plot.
Van Calster et al. also proved that moderate calibration guarantees that clinically harmless
decisions are made based on the model. The calibration plots presented in this study show
both level 1, where the ideal case is a 45-degree line with a slope coefficient 1 and intercept
0 (Steyerberg, Van Calster & Pencina, 2011), and level 3 calibration.
To validate the predictive models, we performed repeated cross-validation. More
specifically, 10-fold cross validation was used, whereby we randomly split data into 10
training/test sets for each model. We repeated this step 10 times, therefore we ended up
with 100 experiments for each dataset. Instances in each fold were randomly selected. To
evaluate and directly compare the models, the following two metrics were considered:
AUC and Area Under the Precision Recall Curve (AUPRC). Similarly to AUC, AUPRC
summarises the Positive Predictive Value (i.e, ratio of correctly classified positive values
to the number of all instances classified as positive) over TPR curve into one number.
AUPRC can often be more informative than AUC, especially for unbalanced datasets (Saito
& Rehmsmeier, 2015), which was the case for the CVD dataset in this work.
Interpretability of models was measured by the number of selected variables in each
experiment. We reported the following results: (a) number of all variables, and (b) number
of all variables that were selected in all repetitions of the experiments for different MND
values (i.e., stable variables). In addition, a medical doctor manually inspected all selected
variables for MND = {10, 20, 50} to evaluate the interpretability (i.e., extracted knowledge
in form of variables from the logistic regression models) of the models from the medical
point of view.
RESULTS
This section presents the results in terms of predictive performance, calibration and selected
variables for both CVD and T2D datasets. All results are reported for both datasets with
different MND values to observe the influence of model complexity on performance.
Predictive performance
Box plots in Figs. 2 and 3 illustrate AUC and AUPRC values for both chronic diseases and
different MND values ranging from 10 to 100 and an additional model with no dimension
reduction (NDR).
One can observe stabilisation of both performance metrics in both datasets immediately
after the MND is increased from 10 to 20. Even though a small increase in predictive
performance can be observed when the complexity of the model increases, it is not
significant, especially when MND increases to 50 and more selected variables.
More detailed predictive performance results including sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), average number of selected
features and percentage of positively predicted cases can be found in Supplemental
Informations 1 and 2.

















































Figure 3 Boxplots of CVD and T2D AUPRC values with 100 iterations at different MND values.
Full-size DOI: 10.7717/peerj.5765/fig-3
Calibration plots
Figure 4 presents the calibration plots for both chronic conditions. Due to space limitations,
we show calibration plots only for MND = {10, 20, 50, 100, NDR}. The vertical axis of
a calibration plot represents observed proportion of the class, while the horizontal axis
represents the predicted probability.
Observing the calibration plots it can be noticed that the more complex models result
in better calibration. However, the calibration improves significantly with the MND at 20
or higher.

































































































































































Figure 4 Calibration plots for CVD (A–E) and T2D (F–J) for average probabilities and different MND
values. Predicted probabilities from each fold were saved and averaged over 10 repetitions. For each cali-
bration plot in the upper left corner the intercept value (‘‘in the large’’) and slope is shown together with
the AUC value or c-statistic. The main part of the plot is a flexible calibration curve based on restricted
cubic splines, with a pointwise 95% confidence interval (dashed lines), followed by a case/non case his-
togram at the bottom.
Full-size DOI: 10.7717/peerj.5765/fig-4
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Table 3 Number of all and stable selected variables in all experimental repetitions.Number of stable variables is presented in brackets.
MND 10 20 30 40 50 60 70 80 90 100 NDR
CVD 9 (4) 21 (15) 32 (17) 47 (25) 66 (29) 75 (30) 89 (31) 107 (32) 119 (32) 125 (33) 389 (43)
T2D 11 (4) 21 (12) 37 (14) 52 (14) 71 (14) 81 (14) 91 (15) 102 (15) 126 (17) 146 (18) 352 (23)
Table 4 Ratio of all and stable selected variables in all experimental repetitions. Ratio of stable variables is presented in brackets.














































Due to space limitations, we list all selected variables for different experimental settings
in Supplemental Informations 1 and 2, while Table 3 (Table 4) summarises the number
(ratio) of (a) all variables, and (b) variables that were selected in all repetitions of the
experiments for different MND values (i.e., stable variables) and NDR. Please note, that
the number of all selected variables in an experiment can be higher than the experiment’s
MND parameter, since we repeat each experiment 100 times and its selected variables do
not necessarily always overlap (which is the case for stable variables).
DISCUSSION
In this study, we found that it is possible to use drug prescription data to build a model for
polypharmacy prediction. Results on Figs. 2 and 3 (details in Supplemental Informations
1 and 2) show the maximum AUC (95% CI) values of 0.900 (0.898–0.901) and 0.808
(0.803–0.812) for CVD and T2D respectively, while AUPRC (95% CI) reaches maximum
values of 0.640 (0.635–0.645) and 0.732 (0.725–0.739) for CVD and T2D respectively.
We see that the difference between AUC and AUPRC was lower for T2D compared to
CVD. The CVD dataset is skewed towards negative class and consists of 21,8% positive
cases (compared to 44.9% positive cases in T2D). It was shown, that AUC can bemisleading
in terms of the reliability of classification performance in imbalanced datasets, whereas
AUPRC can provide an accurate prediction of classification performance, since they
evaluate true positive amongst positive predictions (Saito & Rehmsmeier, 2015).
In addition, the study showed that it is feasible to find a balance between good
performance and interpretability of the model. Figure 2 shows a slow decrease of the
AUC performance for both datasets when complexity is controlled with MND. The
difference with the maximum AUC values with dimensionality reduction is most notable
with MND = 10, where AUC drops below 0.750 for both medical conditions. However,
we can notice that increasing MND to 20, already improves performance significantly.
Specifically, AUC of 0.875 (0.873–0.877) and 0.782 (0.777–0.787) is achieved for CVD and
T2D respectively. The difference in AUC performance for MND = 20 compared to NDR
is only 3% and 4% for CVD and T2D respectively, while Table 4 shows that only 5% and
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1% of all variables have been kept for CVD and T2D respectively (35% and 52% of stable
variables). The ratio between reduced complexity and decreased performance gets even
smaller with higher MND values. For example, the maximum AUC value of 0.90 for CVD
is achieved with MND = 50, with only 13% variables kept (67% stable variables).
Similarly to AUC in Fig. 2, results in Fig. 3 show how AUPRC changes when we control
MND. The lowest performance was obtained for MND = 10, while already with MND =
20, AUPRC values reach 96% (0.607) and 95% (0.703) of the maximum AUPRC values
for CVD and T2D, respectively.
The AUC and AUPRC results show that while medical experts are able to work with
much less complex models when reducing MND, this does not mean that they have to
significantly sacrifice performance of the model.
The study also showed that it is possible to achieve acceptable calibration when reducing
complexity of the model. Calibration plots presented in Fig. 4 show the correlation between
calibration and complexity of the model. Van Calster et al. (2016) recommend that strong
calibration should be desirable in cases of individualized decision support, but often
stimulates too complex models and might even be counterproductive in other cases. Our
results confirm this recommendation as the models with the best calibration result in the
highest number of selected variables, but without significant improvement of predictive
performance. Further recommendation byVan Calster et al. (2016) introduces the so called
moderate calibration defined by equality of the average predicted and the actual average
risk. Moderate calibration can be observed in all models presented in our study.
Interpretation of selected variables by a medical doctor revealed that both CVD and T2D
seem to be associated with polypharmacy independently of other medication (Bjerrum
et al., 1998; Jyrkkä et al., 2009). Moreover, in our models for both CVD and T2D, a
large proportion of selected medications suggest other clinical conditions that were
reported in a review of nine studies to be associated with polypharmacy, e.g., depression,
asthma, and gout (Hajjar, Cafiero & Hanlon, 2007). Further, some of the groups of drugs
strongly suggest patient conditions other than well-defined diseases, such as declining
nutrition and cognitive capacity that were also reported to be independently associated with
polypharmacy (Jyrkkä et al., 2011). Concerning particular groups of drugs as predictors
of polypharmacy, studies show large variation and this is further complicated by the fact
that study settings differ as well (Hovstadius & Petersson, 2012). In a large study of an
entire national population, Hovstadius et al. (2010) have found that the five most often
prescribed drug groups in patients receiving polypharmacy were (listed in decreasing
order occurrence) antibacterials, analgesics, psycholeptics, antithrombotic agents, and beta
blocking agents. In our study, analgesics and psycholeptics were included as features across
all models for both CVD and T2D. Beta-blockers were excluded in the CVD group, but
included in all of the models for T2D. Interestingly, in our case antibacterials were included
only in the CVD model and the antithrombotic agents were robust predictive features for
the T2D model, whereas they were included in the CVD model only above MND = 50.
Among the features most consistently selected in our models for both CVD and
T2D were psycholeptics, psychoanaleptics, and antiepileptics. It should be noted that
particularly the latter are sometimes used for indications other than epilepsy, e.g., mood
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stabilization. However, our finding corresponds with previous reports that people with
mental health conditions and behavioral problems are at an increased risk for polypharmacy
in general (O’Dwyer et al., 2016; Peklar et al., 2017) and that long-term use of some of the
drugs from these groups carries the risk of metabolic dysregulation (Gareri et al., 2006),
falls (Peklar et al., 2017) or even cognitive decline (Jenkins, 2000), which may precipitate a
vicious cycle of receiving an increasing number of drugs.
Interestingly, compared with other studies reporting that women are more likely to
receive polypharmacy (Bjerrum et al., 1998; Haider et al., 2008; Qato et al., 2008) and that
increasing age is a key determinant of polypharmacy exposure (Hovstadius & Petersson,
2012; Jyrkkä et al., 2009; Hajjar, Cafiero & Hanlon, 2007; Stewart & Cooper, 1994), in our
sample, no robust association was found between polypharmacy and gender, and age was
a feature selected only for the CVDmodel above MND= 10. It is possible that some of the
features selected in models yielding better prediction might not reflect worsening physical
health and thus a greater biological need for polypharmacy due to true multimorbidity,
but may reflect patient transfer to an institution or change in residency, since it has been
found that some of the medications that were robustly selected in our models are more
frequently reported for patients in residential, as compared to community group homes
or those living independently (O’Dwyer et al., 2016) and that nursing home residents are
at an increased risk for polypharmacy (Vetrano et al., 2013).
The addition of diagnosis data (inpatient ICD codes) showed little improvement in
our models, both in terms of gain in AUC or AUPRC and in terms of selected features
in the models. Our explanation for this outcome is twofold; firstly there were only 13.3%
hospitalization associated with CVD cases and even less 12.6% with T2D cases, which
gives us a sparse matrix with little information gain. Secondly, drug prescriptions are
usually to some degree associated with diagnoses of hospitalizations especially for elder
chronic patients, which lowers the information gain for these features in our models even
more. Secondly, drug prescriptions are usually to some degree associated with diagnoses
of hospitalizations (Klarin, Wimo & Fastbom, 2005) especially for older chronic patients,
which lowers the information gain for these features in our models even more.
The present study has some limitations that should be taken into the consideration.
First, the data was restricted only to patients with at least one prescribed medication
for either CVD or T2D. Second, since the records contain only month and year of the
prescription or hospital admission, this influences our definitions for concurrent use of
drugs, polypharmacy and chronic disease. Third, due to age groups, we were able to only
estimate years of birth. Finally, a set of ATC codes for CVD was based on previous work of
Huber et al. (2013).
CONCLUSION
In this study we developed models to predict polypharmacy based on drug prescription
and hospital discharge datasets. We focused on two common chronic conditions, i.e., CVD
and T2D, since both are known to increase the risk of polypharmacy. Based on a centrally
collected national prescription dataset, we defined and performed electronic phenotyping
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of chronic CVD and T2D patients with/and without polypharmacy. We also measured
how increasing interpretability of predictive models by decreasing the number of variables
included in the final model influences their performance. The interpretability of predictive
models is important for the application of the proposed model in practice, especially in the
context of learning healthcare systems where models are continuously adapted.
In the future, we plan to investigate performance of our models on other diseases
and apply deep learning (DL) algorithms (Miotto et al., 2017). With DL, we expect less
interpretable models with increased performance.We believe that our work has potential to
positively influence drug prescription practices as discussed in Molokhia & Majeed (2017).
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